{"abstract":"The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Commercialization Patent License to PaxVax, Inc., located in Redwood City, California, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/10/12/2017-21986.html","cfr_references":[],"citation":"82 FR 47537","comment_url":null,"comments_close_on":"2017-11-13","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before November 13, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2017-21986","effective_on":null,"end_page":47538,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/10/12/2017-21986.xml","html_url":"https://www.federalregister.gov/documents/2017/10/12/2017-21986/prospective-grant-of-exclusive-patent-license-dna-based-vaccine-for-prevention-of-zika-virus","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-21986?publication_date=2017-10-12","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-10-12/2017-21986/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":986,"last_updated":"2026-07-26 00:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-10-12/pdf/2017-21986.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-21986.pdf?1507725943","publication_date":"2017-10-12","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/10/12/2017-21986.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T20:20:11Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":47537,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: DNA-Based Vaccine for Prevention of Zika Virus Infection","toc_doc":"DNA-based Vaccine for Prevention of Zika Virus Infection","toc_subject":"Prospective Grant of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":82}